Article
Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.
Oncotarget - 19 Apr 2016
Wang Xiaochun, Goldstein David, Crowe Philip J, Yang Mark, Garrett Kerryn, Zeps Nikolajs, Yang Jia-Lin
Abstract excerpt
Although epidermal growth factor receptor (EGFR) is often over-expressed in soft tissue sarcoma (STS), a phase II trial using an EGFR inhibitor gefitinib showed a low response rate. This study identified a new secondary resistance mechanism of gefitinib in STS, and developed new strategies to improve the effectiveness of EGFR inhibition particularly by blocking the STAT3 pathway.We demonstrated that seven STS...
Topics
Join the communities discussing this publication.